NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.

Michael CecchiniJames M ClearyYu ShyrJoseph ChaoNataliya UbohaMay ChoAnthony ShieldsShubham PantLaura GoffKristen SpencerEdward J KimStacey SteinJeremy S KortmanskySandra CanosaJeffrey SklarElizabeth M SwisherMarc RadkePercy IvyScott BoernerDiane E DureckiChih-Yuan HsuPatricia LoRussoJill Lacy

Published in: British journal of cancer (2023)

Olaparib and ramucirumab is well-tolerated with efficacy that exceeds historical controls with ramucirumab single agent for gastric cancer in a heavily pre-treated patient population.

Keyphrases

squamous cell carcinoma
small cell lung cancer
case report
open label
newly diagnosed
clinical trial
randomized controlled trial
double blind